Improving specificity for ovarian cancer screening using a novel extracellular vesicle-based blood test – Performance in a training and verification cohort

• Published in: The Journal of molecular diagnostics : JMD
• Main Authors: Winn-Deen, Emily S., Bortolin, Laura T., Gusenleitner, Daniel, Biette, Kelly M., Copeland, Karen, Gentry-Maharaj, Aleksandra, Apostolidou, Sophia, Couvillon, Anthony D., Salem, Daniel P., Banerjee, Sanchari, Grosha, Jonian, Zabroski, Ibukunoluwapo O., Sedlak, Christopher R., Byrne, Delaney M., Hamzeh, Bilal F., King, MacKenzie S., Cuoco, Lauren T., Duff, Peter A., Manning, Brendan J., Hawkins, Troy B., Mattoon, Dawn, Guettouche, Toumy, Skates, Steven J., Jamieson, Amy, McAlpine, Jessica N., Huntsman, David, Menon, Usha
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 24.09.2024
• ISSN: 1525-1578; 1943-7811; 1943-7811
• DOI: 10.1016/j.jmoldx.2024.09.001

The low incidence of ovarian cancer (OC) dictates that any screening strategy needs to be both highly sensitive and highly specific. This study explored the utility of detecting multiple colocalized proteins or glycosylation epitopes on single tumor-associated extracellular vesicles (EVs) from blood. The novel OC Test employs immunoaffinity capture of tumor-associated EVs followed by proximity-ligation qPCR to detect combinations of up to three biomarkers to maximize specificity and measures multiple combinations to maximize sensitivity. A high-grade serous carcinoma (HGSC) case-control training set of EDTA plasma samples from 397 women was used to lock down the test design, the data interpretation algorithm, and the cut-off between cancer and non-cancer. Performance was verified and compared to CA125 in an independent blinded case-control set of serum samples from 390 women (132 controls, 66 HGSC, 83 non-HGSC OC, 109 benign). In the verification study, the OC Test showed a specificity of 97.0% (128/132; 95% CI: 92.4%-99.6%), a HGSC sensitivity of 97.0% (64/66; 95% CI: 87.8%-99.2%), and an AUC of 0.97 (95% CI 0.93-0.99) and also detected 73.5% (61/83; 95% CI: 62.7%-82.6%) of the non-HGSC OC cases. This test exhibited fewer false positives in subjects with benign ovarian tumors, non-ovarian cancers, and inflammatory conditions when compared to CA125. The combined sensitivity and specificity of this new test suggests it may have potential in OC screening.